Ocrevus, ABP 692, Ocrevus 300 mg concentrate for solution for infusion
20230309
Phase 3 small_molecule active
Quick answer
Ocrevus, ABP 692, Ocrevus 300 mg concentrate for solution for infusion for Relapsing-remitting Multiple Sclerosis is a Phase 3 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- Relapsing-remitting Multiple Sclerosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active